one.bio

one.bio is an emerging biotechnology startup founded in 2019 with a focus on creating novel prebiotics, synbiotics, and immuno-modulatory therapies from natural carbohydrates. The company's proprietary technology allows it to produce oligosaccharides from natural products, catering to the food and beverage as well as biopharmaceutical industries. With its emphasis on modulating the microbiome and immune function, one.bio has attracted significant attention and recently secured a $12.00M Series A investment on 13 April 2022. The investors in this funding round included Seventure Partners, Acre Venture Partners, Collaborative Fund, iSelect, and Skyviews Life Science, positioning one.bio for rapid growth and future industry impact. With its innovative approach and strategic investments, the company is well-positioned to drive meaningful change in the biotechnology and healthcare sectors.